Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Adenomatous Polyposis Coli

erlotinib hydrochloride has been researched along with Adenomatous Polyposis Coli in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80

Authors

AuthorsStudies
Burke, CA; Buttar, N; Cruz-Correa, M; Das, R; Della'Zanna, G; Foster, N; Kanth, P; Limburg, PJ; Mankaney, G; McMurray, RP; Richmond, E; Rodriguez, LM; Samadder, NJ; Sossenheimer, M; Stoffel, E; Szabo, E; Thirumurthi, S; Turgeon, DK; Umar, A; Vilar, E; Westover, M; Zahrieh, D1
Burke, CA; Chick, RC; Cindass, JL; Clifton, GT; Ensley, DC; Hale, DF; Hickerson, AT; Kemp Bohan, PM; Mankaney, G; Peoples, GE; Sohn, V; Vreeland, TJ1
Brown, PH; Dashwood, RH; Dashwood, WM; Gustafson, TA; Kapoor, S; Mohammed, A; Rajendran, P; Savage, MI; Sei, S; Ulusan, AM; Vilar, E; Yavuz, OF1
Berry, T; Boucher, KM; Burt, RW; Byrne, K; Jasperson, K; Jones, D; Kanth, P; Kuwada, SK; Neklason, DW; Pappas, L; Samadder, NJ; Samowitz, W; Sample, D; Smith, L; Tavtigian, SV; Westover, M1
Baker, H1

Reviews

1 review(s) available for erlotinib hydrochloride and Adenomatous Polyposis Coli

ArticleYear
Chemoprevention in familial adenomatous polyposis: past, present and future.
    Familial cancer, 2021, Volume: 20, Issue:1

    Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Ascorbic Acid; Aspirin; Capsules; Celecoxib; Chemoprevention; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Eflornithine; Erlotinib Hydrochloride; Fatty Acids, Nonesterified; Genes, APC; Humans; Sirolimus; Sulindac; TOR Serine-Threonine Kinases; Vitamins

2021

Trials

2 trial(s) available for erlotinib hydrochloride and Adenomatous Polyposis Coli

ArticleYear
Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
    Gut, 2023, Volume: 72, Issue:2

    Topics: Adenomatous Polyposis Coli; Adult; Duodenal Neoplasms; Duodenum; Endoscopy, Gastrointestinal; Erlotinib Hydrochloride; Female; Humans

2023
Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
    JAMA oncology, 2018, 05-01, Volume: 4, Issue:5

    Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Sulindac; Treatment Outcome

2018

Other Studies

2 other study(ies) available for erlotinib hydrochloride and Adenomatous Polyposis Coli

ArticleYear
Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
    Cancer prevention research (Philadelphia, Pa.), 2021, Volume: 14, Issue:3

    Topics: Adenomatous Polyposis Coli; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colonic Polyps; Disease Models, Animal; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Genes, APC; Intestinal Neoplasms; Male; Mutation; Rats; Sulindac

2021
Sulindac plus erlotinib for familial adenomatous polyposis.
    The Lancet. Oncology, 2016, Volume: 17, Issue:5

    Topics: Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Sulindac

2016